Impact of body size on first‐line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Issue 2 (12th February 2021)

• Record Type: Journal Article
• Authors: Eto, Hiroyuki; Suzuki, Sho; Kusano, Chika; Ikehara, Hisatomo; Ichijima, Ryoji; Ito, Hirotaka; Kawabe, Koichi; Kawamura, Masashi; Yoda, Yoshioki; Nakahara, Moriyasu; Gotoda, Takuji
• Is Part Of: Helicobacter. Volume 26:Issue 2(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-02-12
• Subjects: body size -- dual therapy -- eradication rate; Helicobacter -- Periodicals; Helicobacter infections -- Periodicals; Stomach -- Diseases -- Periodicals; 616.3301405
• DOI: 10.1111/hel.12788
• Languages: English
• ISSNs: 1083-4389

Abstract

Abstract: Background: As a first‐line therapy for Helicobacter pylori, dual therapy with vonoprazan and amoxicillin (VA‐dual) provides an eradication rate similar to that of vonoprazan‐based triple therapy. As the factors associated with the eradication rate of H. pylori with VA‐dual are unknown, we investigated them in this study. Materials and Methods: Overall, 163 patients diagnosed with H. pylori infection received VA‐dual (vonoprazan 20 mg twice daily and amoxicillin 750 mg twice daily for 7 d). The association between successful H. pylori eradication and the following patient clinical factors was analyzed: sex, age, height, weight, body surface area (BSA), body mass index (BMI), history of early gastric carcinoma and peptic ulcer, comorbidity of cirrhosis, alcohol consumption habit, smoking habit, common use of proton pump inhibitors, and concomitant use of drugs that are substratesof cytochrome P450 (CYP) 3A4. The association between post‐eradication adverse events and clinical factors was analyzed retrospectively. Results: Successful H. pylori eradication was associated with a lower BSA (eradication rate: 90.8% in patients with BSA <1.723 vs. 79.6% in those with BSA ≥1.723; p = 0.045). The incidence of adverse events was higher in women than in men (adverse events: 40.0% in women vs. 19.4% in men; p = 0.004). Conclusions: Successful H. pylori eradication with VA‐dual was associated with the small body size of patients. This therapy may have to be adjusted per body size.